Sigma receptor scintigraphy with N-[2-(1'-piperidinyl)ethyl]-3-(123)I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results.
The aim of this study was to investigate the potential of a new iodobenzamide, N-[2-(1'-piperidinyl)ethyl]-3-(123)I-iodo-4-methoxybenzamide (P-(123)I-MBA), to visualize primary breast tumor in humans in vivo. Tumor accumulation of benzamides is based on a preferential binding to sigma receptors that are overexpressed on breast cancer cells.


METHODS
P-(123)I-MBA (148-185 MBq) was administered to 12 patients with a mammographically suspicious breast mass. Two hours after administration, whole-body and spot images of the healthy and the diseased breast were obtained.


RESULTS
A focal increased tracer accumulation was observed in 8 of 10 patients with histologically confirmed breast cancer (mean tumor-to-background ratio, 2.04). No uptake was seen in a case of lymphatic adenitis.


CONCLUSIONS
This preliminary patient study shows that P-(123)I-MBA accumulates in most breast tumors in vivo. Future work should focus on the relationship between P-(123)I-MBA uptake and the proliferative activity of cells to anticipate use of this technique as a tool to noninvasively assess the degree of tumor proliferation.
Caveliers
Vicky
V
Department of Nuclear Medicine, University Hospital, Free University of Brussels, Brussels, Belgium. vickycaveliers@tiscalinet.be
Everaert
Hendrik
H
John
Christy S
CS
Lahoutte
Tony
T
Bossuyt
Axel
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D001943:Breast Neoplasms / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008875:Middle Aged; D010880:Piperidines; D011877:Radionuclide Imaging; D017480:Receptors, sigma / Q000032:analysis*
D001549:Benzamides; D007457:Iodine Radioisotopes; C120391:N-(2-(1'-piperidinyl)ethyl)-3-iodo-4-methoxybenzamide; D010880:Piperidines; D017480:Receptors, sigma